Trials / Terminated
TerminatedNCT01492192
RGD-PET-CT in Cancer Angiogenesis
Prospective Study of 18F-RGD PET-CT in Assessment of Response to Antiangiogenic Treatment in Patients With Cancer and Comparison With Perfusion CT
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Oxford University Hospitals NHS Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical research study is to look at 2 new methods of scanning and see whether they can help researchers predict which tumours will respond to drugs that attack tumour blood supply.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-RGD-PET-CT and perfusion CT scans on 3 occasions | Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis. The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2011-12-14
- Last updated
- 2017-11-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01492192. Inclusion in this directory is not an endorsement.